Tema Cardiovascular and Metabolic ETF (HRTS)

Tema Cardiovascular and Metabolic ETF (HRTS) Financial Services Profile

The Tema Heart & Health ETF (HRTS) provides targeted exposure to companies driving innovation in cardiovascular health, metabolic disorders, and weight management within the biotechnology and broader healthcare sectors. This ETF strategically invests in firms developing cutting-edge treatments and therapies, aiming to capitalize on significant advancements in these critical medical areas.

What Is the Investment Thesis for HRTS?

The Tema Cardiovascular and Metabolic ETF (HRTS) offers investors exposure to a specialized segment of the healthcare industry, focusing on companies addressing cardiovascular health, metabolic disorders, and weight management. With a market capitalization of $51.47M and a Beta of 0.70, HRTS provides a lower volatility option compared to the broader market, while still tapping into high-growth areas. The primary value driver for HRTS is its strategic investment in firms developing cutting-edge treatments, capitalizing on the increasing global prevalence of these diseases. This demand fuels significant research and development, creating a pipeline of potential growth for the ETF's underlying holdings. Key growth catalysts include ongoing advancements in biotechnology leading to new therapeutic breakthroughs and favorable regulatory environments for drug approvals. However, the ETF's performance is inherently linked to the success of its portfolio companies, which face considerable risks from regulatory hurdles, clinical trial outcomes, and intense competition. Investors should monitor developments in healthcare policy and scientific innovation within these specific disease areas, as these factors will significantly influence the long-term performance trajectory of HRTS.

Based on FMP financials and quantitative analysis

HRTS Key Highlights

• Market Capitalization: $0.05 billion, indicating a focused, niche ETF within the asset management sector.
• Beta: 0.70, suggesting lower volatility relative to the broader market, potentially appealing to investors seeking more stable exposure to healthcare innovation.
• Dividend Yield: None, as the ETF does not distribute a dividend, focusing on capital appreciation from its underlying holdings.
• Strategic Investment Mandate: Specifically targets companies developing therapies for cardiovascular health, metabolic disorders, and weight management.
• Exposure to Biotechnology and Healthcare: Provides investors with a diversified basket of companies poised to benefit from cutting-edge developments in these critical industries.

Who Are HRTS's Competitors?

HRTS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are HRTS's Key Strengths?

• Highly focused investment mandate targeting high-growth segments of the healthcare industry.
• Provides diversified exposure to biotechnology and healthcare innovation through an ETF structure.
• Aims to capitalize on the increasing global prevalence of cardiovascular and metabolic diseases.
• Lower Beta (0.70) suggests potentially lower volatility compared to the broader market.

What Are HRTS's Weaknesses?

• Small market capitalization of $51.47M, which can imply lower liquidity or institutional interest.
• No dividend yield, potentially less attractive for income-focused investors.
• Performance is directly tied to the success and regulatory outcomes of a specialized set of underlying companies.
• Concentration risk within a specific thematic niche of the healthcare sector.

What Could Drive HRTS Stock Higher?

• Advancements in biotechnology and drug discovery, particularly for cardiovascular and metabolic diseases, driving innovation within portfolio companies.
• Increasing global prevalence of cardiovascular diseases, metabolic disorders, and obesity, sustaining high demand for related treatments and therapies.
• Potential regulatory approvals for novel drugs or therapies developed by companies within the ETF's portfolio, which could significantly boost their market value and sector sentiment.
• Positive clinical trial results from underlying holdings, demonstrating efficacy and safety for new treatments, thereby enhancing their commercial prospects.

What Are the Key Risks for HRTS?

• Regulatory hurdles and the inherent uncertainty of clinical trial outcomes for underlying pharmaceutical and biotech companies, which can significantly impact their valuation.
• Intense competition within the specialized healthcare and thematic ETF markets, potentially leading to pressure on fees or asset flows.
• Adverse changes in healthcare policy, drug pricing regulations, or reimbursement structures that could negatively affect the profitability of portfolio companies.
• Market volatility specific to the biotechnology and healthcare sectors, which can be influenced by scientific breakthroughs, failures, and investor sentiment.

What Are the Growth Opportunities for HRTS?

• Advancements in Cardiovascular Therapies: The global market for cardiovascular drugs and devices is projected to continue expanding significantly. HRTS is positioned to benefit from companies developing next-generation treatments for heart disease, stroke, and hypertension. Ongoing research into novel drug targets, gene therapies, and minimally invasive procedures represents a substantial growth driver. As of today, 2026-06-14, the pipeline for cardiovascular innovations remains robust, with potential for breakthrough therapies to address leading causes of mortality worldwide, thereby increasing the value of companies focused on these solutions.
• Rising Prevalence of Metabolic Disorders: The increasing global incidence of metabolic disorders, including type 2 diabetes and non-alcoholic fatty liver disease (NAFLD), creates a persistent demand for effective treatments. HRTS invests in companies developing therapies for these conditions, a market that is continually expanding. The development of new drug classes, such as GLP-1 receptor agonists for diabetes and obesity, highlights the significant commercial opportunities. The long-term trend of rising diagnoses ensures a sustained market for innovative solutions, driving growth for the ETF's underlying holdings over the next decade.
• Expansion of Weight Management Solutions: The global obesity epidemic is driving unprecedented demand for effective weight management solutions, including pharmaceuticals. HRTS's focus on companies in this space positions it to capitalize on the rapid growth of this market. The introduction of highly effective anti-obesity medications has transformed the landscape, creating multi-billion dollar opportunities for pharmaceutical companies. This trend is expected to accelerate, with new drug approvals and broader market adoption anticipated in the coming years, presenting a significant growth avenue for the ETF's portfolio companies.
• Biotechnology Innovation and Precision Medicine: The broader biotechnology industry is experiencing a renaissance, with advancements in areas like gene editing, RNA therapies, and personalized medicine. HRTS, by investing in companies within the biotechnology sector, is poised to benefit from these overarching trends. These innovations have the potential to revolutionize the treatment of cardiovascular and metabolic diseases, offering more targeted and effective interventions. The continuous flow of scientific discovery and its translation into clinical applications ensures a dynamic and expanding market for the ETF's underlying investments over the long term.
• Aging Global Population and Healthcare Demand: The global population is aging, particularly in developed economies, leading to an increased prevalence of age-related chronic conditions, including cardiovascular and metabolic diseases. This demographic shift inherently drives greater demand for healthcare services, diagnostics, and pharmaceutical interventions. HRTS's investment mandate directly aligns with this macro trend, as its portfolio companies are developing solutions for conditions that disproportionately affect older demographics. This long-term demographic tailwind provides a stable and expanding market for the ETF's specialized focus areas for decades to come.

What Opportunities Does HRTS Have?

• Continued advancements in biotechnology and pharmaceutical research for cardiovascular and metabolic conditions.
• Growing global demand for effective weight management solutions, including novel therapeutics.
• Expansion into new geographic markets by underlying portfolio companies.
• Increasing investor interest in thematic ETFs that target long-term healthcare trends.

What Threats Does HRTS Face?

• Significant regulatory hurdles and potential clinical trial failures for portfolio companies.
• Intense competition from other healthcare-focused ETFs and actively managed funds.
• Changes in healthcare policy or reimbursement landscapes that could impact drug pricing and profitability.
• Economic downturns or shifts in investor sentiment away from specialized growth sectors.

What Are HRTS's Competitive Advantages?

• Specialized Thematic Focus: Offers a unique and concentrated investment mandate specifically targeting cardiovascular health, metabolic disorders, and weight management, differentiating it from broader healthcare funds.
• Diversified Niche Exposure: Provides a diversified basket of companies within its specific niche, reducing single-stock risk while maintaining thematic purity.
• Strategic Investment Approach: Employs a strategic methodology to identify companies poised for growth from cutting-edge developments in its target areas.

What Does HRTS Do?

The Tema Heart & Health ETF (HRTS) operates within the financial services sector as an asset management product, specifically designed to offer investors focused exposure to the rapidly evolving landscape of biotechnology and healthcare. Established with a clear mandate, HRTS strategically invests in companies that are at the forefront of developing innovative treatments and therapies for critical health challenges. Its core investment focus encompasses firms dedicated to advancing cardiovascular health, addressing metabolic disorders, and pioneering solutions for weight management. This specialized approach allows HRTS to target segments of the healthcare market characterized by significant unmet medical needs and robust research and development activity. The ETF's investment philosophy is rooted in identifying companies poised to benefit from cutting-edge scientific discoveries and technological breakthroughs. By concentrating on cardiovascular diseases, metabolic conditions like diabetes, and the growing global issue of obesity, HRTS aims to capture the value generated by advancements in these areas. The increasing prevalence of these diseases globally drives a continuous demand for novel therapeutic and diagnostic solutions, creating a fertile ground for the companies within the ETF's portfolio. While the specific geographic reach of its underlying holdings is diverse, the ETF itself is headquartered in New York, US, reflecting its positioning within the global financial markets. HRTS provides a diversified basket of companies, offering a mechanism for investors to gain exposure to this specialized healthcare niche without the need for individual stock selection, thereby aligning with the broader trend of thematic ETF adoption in asset management. Its competitive positioning stems from its highly specific thematic focus, differentiating it from more generalized healthcare or biotechnology funds by offering a concentrated play on these interconnected health domains. The ETF's evolution reflects the growing investor interest in targeted thematic investments that capitalize on long-term demographic and scientific trends within the healthcare industry.

What Products and Services Does HRTS Offer?

• Invests strategically in companies within the biotechnology and broader healthcare industries.
• Focuses specifically on firms developing treatments and therapies for cardiovascular health.
• Targets companies addressing metabolic disorders, such as diabetes.
• Includes investments in firms pioneering solutions for weight management.
• Provides investors with exposure to cutting-edge developments in these specialized medical fields.
• Operates as an Exchange Traded Fund (ETF), offering a diversified basket of relevant stocks.
• Aims to capitalize on the increasing global prevalence of cardiovascular and metabolic diseases.

How Does HRTS Make Money?

• Generates revenue primarily through management fees (expense ratio) charged to investors for managing the ETF.
• Seeks to provide capital appreciation for investors by investing in a diversified portfolio of companies.
• Does not directly generate revenue from the sales of products or services of its underlying portfolio companies.
• Its success is measured by the performance of its underlying holdings and its ability to attract and retain assets under management (AUM).

What Industry Does HRTS Operate In?

The Tema Cardiovascular and Metabolic ETF (HRTS) operates within the dynamic asset management industry, specifically carving out a niche in thematic exchange-traded funds. The broader financial services sector has seen a significant trend towards specialized ETFs that offer targeted exposure to specific market segments or megatrends. HRTS positions itself by focusing exclusively on companies involved in cardiovascular health, metabolic disorders, and weight management, areas experiencing substantial growth due to increasing disease prevalence globally. This strategic focus differentiates it from general healthcare or biotechnology ETFs, allowing it to cater to investors seeking concentrated exposure to these interconnected medical fields. The competitive landscape includes numerous other healthcare and thematic ETFs, but HRTS aims to stand out through its precise investment mandate. The demand for innovative treatments in its target areas is robust, driven by an aging population and lifestyle changes, suggesting a sustained market for its underlying investments.

Who Are HRTS's Key Customers?

• Institutional investors seeking thematic exposure to specialized healthcare segments.
• Retail investors looking for diversified access to biotechnology and healthcare innovation.
• Investors focused on long-term growth trends in cardiovascular and metabolic health.
• Portfolio managers aiming to complement existing allocations with targeted healthcare exposure.

How Tema Cardiovascular and Metabolic ETF Is Valued

Relative to its peer group, HRTS's quantitative score of 47/100 is below the peer average of 70/100.

HRTS Financials

HRTS Latest News

HRTS Analyst Consensus

HRTS MoonshotScore

Tema Cardiovascular and Metabolic ETF Financial Services Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources